Cardiac Insight, Inc., a healthcare innovator specializing in wearable cardiac sensors and proven automated electrocardiogram (ECG) analysis, remains committed to delivering highly differentiated benefits to healthcare providers and all patients, including underserved populations. The company remains optimistic despite the recent April 10, 2021 updates to the original January 29, 2021 reimbursement rate decision published by Medicare Administrative Contractor (MAC) Novitas Solutions (Novitas) and First Coast Service Options (First Coast) for CPT codes 93241, 93243, 93245, and 93247.
“Cardiac Insight remains entirely committed to improving the detection of life-threatening cardiac arrhythmias in all patients at risk,” said Brad Harlow, CEO of Cardiac Insight. “We are disappointed to hear iRhythm’s announcement to discontinue serving the Medicare fee for service segment with the ZIO® XT beginning in the second quarter. We will not abandon our customers or patients during these challenging times. Cardiac Insight continues to ensure equitable access to our cost-effective efficient diagnostic solution to all patients, particularly the Medicare and medically underserved populations who have been shown to be at higher risk for complications such as stroke.”
The company advised it will continue to work with Centers for Medicare & Medicaid Services (CMS) and all other MACs to ensure access to long-term extended ECG technologies like the Cardea SOLO™, no matter where in the United States these populations reside. “Full access to technologies should not rely on the decision of a single MAC, which just happens to be where the majority of the service centers are located,” said Bob Odell, President and COO of Cardiac Insight. “Complete access really needs a national coverage determination (NCD), or all of the MACs to reimburse appropriately and equitably. Until this happens, providers are faced with significant challenges to support our seniors and underserved.”
Cardiac Insight provides the only all-inclusive seven-day ambulatory ECG system, the Cardea SOLO™, that enables 100% in-office rapid automated ECG analysis and reporting to detect arrhythmias, including atrial fibrillation. Cardea SOLO™ speeds the time to diagnosis and simplifies the diagnostic process by enabling clinicians to generate an automated report immediately in-house without the need to outsource to third parties.
ABOUT CARDIAC INSIGHT, INC: Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a leading U.S. digital healthcare innovation company specializing in the development of medical-grade, body-worn ECG sensor technology and automated cardiac analysis solutions through its proprietary algorithms and software platforms. The company’s products include the Cardea SOLO™ wearable ECG Sensor and Software Analysis System as well as the Cardea 20/20 ECG™ – the only resting ECG System designed for cardiac risk screening in active youth and athletes at all levels of play. AFib is the most common type of treated heart arrhythmia, with an estimated 2.7 to 6.1 million people in the U.S. living with this arrhythmia. While AFib itself is typically not life-threatening, complications from AFib if left untreated include increased risk for heart problems and heart failure, and increased risk for stroke. AFib is responsible for about one in seven strokes.